Obstructive Sleep Apnea (OSA) - Epidemiology Forecast - 2034

Obstructive Sleep Apnea (OSA) - Epidemiology Forecast - 2034

Key Highlights

DelveInsight’s analyst projects that among the total diagnosed prevalent cases of Obstructive Sleep Apnea (OSA) in 7MM approximately 53% of cases were from the US. As per our estimations, in 2022, the EU4 and the UK accounted for nearly 6,750 thousand diagnosed prevalent cases of Obstructive Sleep Apnea (OSA).

According to the analysis conducted by DelveInsight, Obstructive Sleep Apnea (OSA) was diagnosed in approximately 39% of females and 61% of males within the 7MM in 2022. This analysis indicates a higher prevalence of Obstructive Sleep Apnea (OSA) among females than males.

The highest proportion of OSA cases was estimated in the 65 years and above age group in the 7MM, with an estimated ~8,606 thousand cases, while the least cases were in the age group 19-24 years (~173 thousand cases) in 2022.

DelveInsight’s “Obstructive Sleep Apnea (OSA) – Epidemiology – 2034” report delivers an in-depth understanding of the Obstructive Sleep Apnea (OSA), historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

The United States

EU4 (Germany, France, Italy, and Spain) and the United Kingdom

Japan

Study Period: 2020–2034

Disease Understanding and Diagnostic Algorithm

Obstructive Sleep Apnea (OSA) Overview

OSA is a sleep disorder characterized by recurrent upper airway obstruction during sleep, resulting in disrupted breathing patterns and disturbed sleep quality. Symptoms typically include loud snoring, daytime fatigue, and excessive daytime sleepiness. The prevalence of OSA is increasing, underscoring a significant public health challenge. Despite its widespread occurrence, OSA is frequently underdiagnosed and inadequately managed, highlighting substantial unmet needs within healthcare systems.

Obstructive Sleep Apnea (OSA) Diagnosis

Diagnosing OSA involves polysomnography or home sleep apnea testing. Symptoms, including loud snoring and daytime fatigue, prompt evaluation. Despite its prevalence, OSA often goes unnoticed by the majority of primary care physicians in the United States. Approximately 70–80% of Americans affected by OSA remain undiagnosed and untreated. Left untreated, moderate to severe OSA can significantly increase the risk of developing conditions such as hypertension, heart failure, and other potentially life-threatening ailments.

Underdiagnosis of OSA persists as a significant challenge in healthcare. Many affected individuals remain undiagnosed due to the insidious nature of symptoms, which can often be attributed to other conditions or dismissed as normal. Lack of awareness among patients and healthcare providers, limited access to diagnostic tools, and socioeconomic factors contribute to underdiagnosis. This delay in diagnosis deprives patients of necessary treatment and exacerbates associated health risks.

Further details related to diagnosis are provided in the report…

Obstructive Sleep Apnea (OSA) Epidemiology

For the purpose of designing the patient-based model for Obstructive Sleep Apnea (OSA), the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of Obstructive Sleep Apnea (OSA), Gender-specific Diagnosed Prevalent cases of Obstructive Sleep Apnea (OSA), Age-specific Diagnosed Prevalent cases of Obstructive Sleep Apnea (OSA), and Severity-specific Diagnosed Prevalent cases of Obstructive Sleep Apnea (OSA) in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2020 to 2034. As per DelveInsight’s estimations, the total diagnosed prevalent cases of Obstructive Sleep Apnea (OSA) in the 7MM were approximately 24,907 thousand cases in 2022 and are projected to increase during the forecast period.

The overall count of individuals diagnosed with OSA in the United States was approximately 13,270 thousand in 2022. Given the increasing prevalence of risk factors (obesity rates, aging population, and lifestyle factors exacerbating sleep-related disorders) for OSA in the United States population, the diagnosed prevalence is estimated to increase during the forecast period (2023–2034).

Among the 7MM, EU4 and the UK accounted for nearly 27% diagnosed prevalent cases of Obstructive Sleep Apnea (OSA) in 2022.

Among EU4 and the UK, France had the highest diagnosed prevalent population of OSA, with nearly 1,812 thousand cases, followed by the Germany and the UK in 2022. On the other hand, Spain had the lowest diagnosed prevalent population in EU4 and the UK in 2022.

In Japan, there were around 4,886 thousand diagnosed prevalent cases of OSA in 2022. These cases are expected to increase at a significant CAGR.

Gender-specific diagnosed prevalent cases of Obstructive Sleep Apnea (OSA) showed that males were more affected by OSA than females in the 7MM in 2022.

Males are more affected by OSA than females due to anatomical differences such as narrower airways, increased neck circumference, and hormonal factors like testosterone levels, which contribute to higher muscle mass and collapsibility of the upper airway during sleep. Additionally, lifestyle factors and genetic predispositions may also play a role in this gender discrepancy.

Age-specific diagnosed prevalent cases of Obstructive Sleep Apnea (OSA) were distributed in the age groups 0-18 years, 19-24 years, 25-34 years, 35-44 years, 45-54 years, 55-64 years, and 65 years and above.

The highest proportion of OSA cases was estimated in the 65 years and above age group, followed by 55-64 years in the 7MM, while the least cases were in the age group 0-17 years. Elevated OSA rates among those aged 65 and above stem from age-related factors like muscle tone decline, obesity risks, altered sleep patterns, and comorbidities.

As per the DelveInsight model, the severity-specific diagnosed prevalent OSA cases were categorized into mild, moderate, and severe. In 2022, there were highest cases of severe OSA (~5,986 thousand), followed by mild OSA (~4,122 thousand) in the US.

KOL Views

To gaze into the epidemiology insights of the real world, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate the secondary research. Industry Experts were contacted for insights on Obstructive Sleep Apnea (OSA) evolving diagnostic landscape, patient reliance on conventional therapies, patient therapy switching acceptability, along with challenges related to accessibility, including KOL from Wayne State University School of Medicine, the US; Clinic for Pneumology and Allergology, Centre of Sleep Medicine and Respiratory Care, Solingen, Germany; University of Palermo and CNR Institute of Biomedicine and Molecular Immunology (IBIM), Palermo, Italy; Respiratory Dept. Hospital Universitario y Politécnico La Fe, Valencia, Spain, Japanese Society of Sleep Research, Japan, and others.

Delveinsight’s analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Their opinion helps understand and validate current disease prevalence, gender involved with the disease, diagnosis rate, and diagnostic criteria.

Scope of the Report

The report covers a segment of key events, an executive summary, descriptive overview of Obstructive Sleep Apnea (OSA), explaining its causes, signs and symptoms, and pathogenesis.

Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and diagnostic guidelines.

The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.

A detailed review of current challenges in establishing the diagnosis.

Obstructive Sleep Apnea (OSA) Report Insights

Patient Population

Country-wise Epidemiology Distribution

Diagnosed Prevalence of Obstructive Sleep Apnea (OSA)

Gender-specific Diagnosed Prevalence of Obstructive Sleep Apnea (OSA)

Age-specific Diagnosed Prevalence of Obstructive Sleep Apnea (OSA)

Severity-specific Diagnosed Prevalence of Obstructive Sleep Apnea (OSA)

Obstructive Sleep Apnea (OSA) Report Key Strengths

12 years Forecast

The 7MM Coverage

Obstructive Sleep Apnea (OSA) Epidemiology Segmentation

Key Questions

Epidemiology Insights

What are the disease risks, burdens, and unmet needs of Obstructive Sleep Apnea (OSA)? What will be the growth opportunities across the 7MM concerning the patient population of Obstructive Sleep Apnea (OSA)?

What is the historical and forecasted Obstructive Sleep Apnea (OSA) patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?

Why do only limited patients appear for diagnosis?

Which country is more prevalent for Obstructive Sleep Apnea (OSA) and why?

What factors are affecting the diagnosis of the indication?

Reasons to Buy

Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.

To understand the Obstructive Sleep Apnea (OSA) diagnosed prevalent cases in varying geographies over the coming years.

A detailed overview of Severity, Gender, and Age-specific diagnosed prevalence of Obstructive Sleep Apnea (OSA).

To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis options.

Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.

Frequently Asked Questions

1. What is the forecast period covered in the report?

The Obstructive Sleep Apnea (OSA) Epidemiology report for the 7MM covers the forecast period from 2023 to 2034, providing a projection of epidemiology dynamics and trends during this timeframe.

2. Out of all EU4 countries and the UK, which country had the highest population of Obstructive Sleep Apnea (OSA) cases in 2022?

The highest cases of Obstructive Sleep Apnea (OSA) was found in the France among EU4 and the UK in 2022.

3. How is epidemiological data collected and analyzed for forecasting purposes?

Epidemiological data is collected through surveys, clinical studies, health records, and other sources. It is then analyzed to calculate disease rates, identify trends, and project future disease burdens using mathematical models.

4. Out of all 7MM countries, which country had the highest population of Obstructive Sleep Apnea (OSA) cases in 2022?

The highest cases of Obstructive Sleep Apnea (OSA) were found in the US among the 7MM in 2022.